Trial Results

Care guides can help patients and caregivers understand long-term side effects of blood and marrow transplant (BMT), according to a new study.

Many people don’t have a fully matched family or unrelated donor for a lifesaving blood or marrow transplant (BMT). Now, a new treatment may help more people have a safe mismatched BMT. 

Some people with Medicaid insurance face delays or other problems getting blood and marrow transplant (BMT) for sickle cell disease. 

Children who have blood cancers are less likely to survive after transplant if their families are low-income compared to children from higher-income families, a new study found. 

Researchers created a tool to help doctors choose the best treatments for children with leukemia. The tool is called the Pediatric Disease Risk Index. 

Scientists say a medicine called sirolimus can treat acute graft-versus-host disease (GVHD) and causes fewer side effects than older medicines. 

Scientists found a new combination of medicines that helps prevent graft-versus-host disease (GVHD). The medicines also help people with blood cancers live longer. 

A group of doctors who specialize in blood and marrow transplants, or BMT, now recommend CAR T-cell therapy in some cases. 

Staff at blood and marrow transplant (BMT) centers want to help people return to work after transplant. But there is little guidance, according to research. 

Blood and marrow transplant (BMT) is a highly complex treatment that can affect health for years afterward. Patients, caregivers and families receive a lot of information throughout BMT. 

 Be The Match Registry® overcomes COVID-19 challenges 

Largest study so far shows that most patients survive 

A small number of people regret having a blood or marrow transplant (BMT) within 6 to 12 months, research shows. 

Most studies of blood and marrow transplant (BMT) do not include babies younger than age 1. 

More people with leukemia who had intense treatment just before blood or marrow transplant (BMT) got a bacterial infection, compared to people who had less intense treatment. 

Very high doses of irradiation before blood or marrow transplant (BMT) are only as helpful as standard high doses, according to a new study. 

Research showing that cells can be carefully frozen and stored for blood and marrow transplant (BMT) will save lives during the COVID-19 pandemic and beyond. 

Only 1 in 5 African Americans who need a blood or marrow transplant (BMT) can find a matched donor. A transplant from a half-matched or cord blood donor also can help, a new study shows. This may allow more African Americans to get a life-saving transplant. 

Blood or marrow transplant (BMT) can help people with severe sickle cell disease, but little was known about the best age for a person to get BMT or which type of donor is best. 

About 1 out of 4 teens or young adults who had blood or marrow transplants (BMT) to cure leukemia had at least 1 late side effect several years later. 

A haploidentical, or haplo, blood or marrow transplant (BMT) can help people with acute myeloid leukemia (AML), research shows. AML is a blood cancer that may be cured with BMT. 

Blood and marrow transplant (BMT) is helpful for older people, but only 5-10% of older people who need BMT get this lifesaving treatment. 

Although BMT is the only known cure for MDS, many people aren’t aware of BMT or think that they’re too old to have one because of its side effects.

Although blood and marrow transplant (BMT) can cure leukemia and lymphoma, some people can’t find a fully matched donor. And people with diverse ethnic backgrounds may have more difficulty finding a match. 

Memory problems might affect physical health during blood and marrow transplant (BMT), researchers say. Extra therapy may help. 

The largest study of its kind found that unlicensed umbilical cord blood is safe and effective for umbilical cord blood transplant (UCBT). 

In this study, researchers learned that people older than 50 with acute leukemia live longer after a blood or marrow transplant (BMT) from a young, matched unrelated donor than from a half-matched family member. 

For multiple myeloma, doctors recommend a single autologous blood or marrow transplant followed by only lenalidomide maintenance, instead of more intensive treatments. That’s news from a study that compared 3 treatments. 

People who need a life-saving blood or marrow transplant (BMT) need to be especially careful to avoid COVID-19 

 A small study found that blood or marrow transplant (BMT) may preserve intelligence in children with sickle cell disease.

A new online calculator helps doctors decide when it’s safest to stop immune suppression medicines after blood or marrow transplant (BMT). This is important because, while these medicines protect against graftversus-host disease (GVHD), they also increase the risk of infections. 

A CAR T-cell therapy helps hard-to-treat cases of lymphoma and leukemia, according to a large study. 

Young adults who’ve had allogeneic blood and marrow transplant (BMT) are less likely to be employed than their peers. 
 

 Half-matched donors are acceptable if no match is found.

People with lymphoma should get a blood or marrow transplant (BMT) before trying newer chimeric antigen receptor T cell (CAR-T) therapy. 

Doctors should not give certain antibiotics to children with leukemia during blood or marrow transplant (BMT). 

The US Food and Drug Administration (FDA) recently approved abatacept as the first medicine to prevent acute graft-versus-host disease (GVHD). 

Both help people who have acute leukemia but no matched donor.

Most children who have had blood or marrow transplant (BMT) may need to delay returning to school until they have been fully vaccinated for COVID-19. 

A recent clinical trial compared 2 new short-term treatments against 1 standard long-term treatment. The new treatments were not better than the standard, but all 3 treatments had the same proportion of patients who were alive without cancer relapse or significant CGVHD. 

Blood or marrow transplant (BMT) can cure sickle cell disease for some people. Now, doctors can predict which people will benefit most from BMT. 

Most people who live for 2 years or longer after their blood or marrow transplant (BMT) are cured of their disease and can expect to live for many more years. That’s according to new research on BMT and sickle cell disease. 

Both race and genes may affect how well blood or marrow transplant (BMT) works, according to a new study. 

A group of doctors, researchers, and patient advocates published a review of scientific research. They said that BMT sometimes causes problems with hormones and sperm. Also, BMT may cause graft-versus-host disease (GVHD) and secondary cancers that impact the penis, testes, and scrotum. 

Blood and marrow transplant (BMT) can control multiple myeloma, a blood cancer. By 1 year after BMT, most people have good quality of life, according to a new study. 

Doctors should team up to diagnose acute graft-versus-host disease, or aGVHD, more accurately. That’s according to new research. 

aGVHD is one of the most common complications after blood or marrow transplant (BMT). AGVHD can start in the first 3 months after BMT but sometimes occurs later. About 90% (9 out of 10 patients) have symptoms that may indicate aGVHD after BMT.

 Moderate-intensity exercise, like biking, swimming, or fast-paced walking, can help people with sickle cell disease make more blood vessels in their muscles. That’s according to new research.

For younger patients with multiple myeloma, getting a blood or marrow transplant (BMT) is sometimes better than using newer combinations of medicines alone. Now, preparatory therapy can be adjusted to meet individual patients’ needs. 

There are 3 sources for BMT: bone marrow, peripheral blood stem cells, and umbilical cord blood. These can come from fully matched or half-matched donors. A new study shows that for a person with leukemia or lymphoma, if a fully matched donor is not available, a halfmatched donor is better than umbilical cord blood.

Blood and marrow transplant (BMT) can help people who have a rare blood cancer. T-cell prolymphocytic leukemia (T-PLL) is hard to treat— medicines alone typically are not enough for a long-term cure. New research shows that BMT is useful for some people who have this disease. 

People of all races and ethnicities can get successful transplants for severe aplastic anemia (SAA), according to a new study. 

More older people with acute myeloid leukemia (AML) should get blood and marrow transplant (BMT), according to a new study. 

The medicine cyclophosphamide may reduce serious digestive problems after blood or marrow transplant (BMT). That’s according to a new study of about 1,400 people who got BMT for blood cancers, including leukemia and myelodysplastic syndromes. 

Although blood or marrow transplant (BMT) can cure blood cancers, sickle cell disease, and other conditions, it also has side effects. A new study of long-term quality of life after BMT shows that young adults, aged 18 to 39, may have lower quality of life than adults aged 40 and older. 

About 4 out of every 10 children who get blood or marrow transplant (BMT) have effects 10 years later. 

Blood and marrow transplant (BMT) is the only cure for myelodysplastic syndromes (MDS), a blood cancer. However, BMT can have serious side effects. 

Mismatched blood or marrow transplant (BMT) is a newer option that helps people survive blood cancers. That’s according to a study of people 3 years after BMT 

A year after blood or marrow transplant, most cancer survivors have low levels of physical and mental distress

New medicines have helped people to get a life-saving blood or marrow transplant (BMT) even if they don’t have a fully matched donor. 

A newer type of blood or marrow transplant (BMT) is cost-effective and should be covered by insurance in the US. That’s a recommendation from researchers, after a new study